Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01024569 · ClinicalTrials.gov registry record · NA

Randomized Controlled Trial of Wellness Recovery Action Planning

A NA study, sponsored by University of Illinois at Chicago.

Completed
Registry status
NA
Development phase
555
Enrollment target

NCT01024569: Completed NA study, sponsored by University of Illinois at Chicago.

NCT01024569 is a NA study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 555 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01024569, a NA study, has completed, sponsored by University of Illinois at Chicago.

COMPLETED
Registry status
NA
Development phase
555 participants
Enrollment target

Study Summary

The purpose of this research study is to test the effectiveness of a standardized peer-led intervention to teach self-management skills in improving outcomes of individuals with a severe mental illness. The intervention is known as Wellness Recovery Action Planning or WRAP, co-developed by Dr. Mary Ellen Copeland. The focus of the inquiry is on whether and how developing an individualized plan for successful living: 1) lowers psychiatric symptoms; 2) enhances psychosocial outcomes such as self-perceived recovery, empowerment, self-advocacy, coping, and social support; 3) increases knowledge of personal mental illness self-management strategies; and 4) enhances satisfaction with the service delivery system. The study evaluated the following hypotheses: Hypothesis #1: Compared to wait-list control subjects, those who participate in the WRAP intervention will report reduced levels of psychiatric symptoms. Hypothesis #2: Compared to wait-list control subjects, those who participate in the WRAP intervention will report enhanced enhanced feelings of empowerment, hope, recovery, quality of life, and functioning. Hypothesis #3: Compared to wait-list controls, those who participate in the WRAP intervention will report increased levels of social support. Hypothesis #4: Compared to wait-list controls, those who participate in the WRAP intervention will report increased use of peer services, higher satisfaction with services, and have lower overall service costs. Hypothesis #5: Compared to controls, those who participate in the WRAP intervention will report increased knowledge of mental illness self-management, including making/using a WRAP plan. Hypothesis #6: There will be no difference in employment rates of control vs. intervention subjects.

Primary Outcome

The BSI is a patient self-report mental health symptoms research instrument (Piersma et al., 1994). Respondents are asked how much they were bothered in the past week by 53 symptoms on 9 dimensions with a 5-point response scale ranging from ''not at all'' to ''extremely.'' We assessed the BSI Positive Symptom Score which captures the number of symptoms endorsed in a pathological direction, representing the total volume of different symptoms reported to be present to any degree. The minimum value

Interventions

  • BEHAVIORAL Wellness Recovery Action Planning (WRAP)

Trial Details

FieldValue
Enrollment Target 555 participants
Start Date 2007-12
Est. Completion 2009-10
Phase NA
University of Illinois at Chicago

430 total trials

What the finished NCT01024569 record still lists

NCT01024569 is an interventional study that assigns participants to a tested intervention. The registered 555 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower).

The record links to 0 conditions, and to 1 intervention - of which Wellness Recovery Action Planning (WRAP) is the first listed.

NCT01024569 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01024569 about?

NCT01024569 is a clinical study titled "Randomized Controlled Trial of Wellness Recovery Action Planning". The purpose of this research study is to test the effectiveness of a standardized peer-led intervention to teach self-management skills in improving outcomes of individuals with a severe mental illness. The intervention is known as Wellness Recovery Action Planning or WRAP, co-developed by Dr. Mary ...

What is the current status of trial NCT01024569?

This trial is currently completed. It is a NA study. The enrollment target is 555 participants. The study started on 2007-12. Estimated completion is 2009-10.

What interventions are being tested in trial NCT01024569?

The interventions under investigation include: Wellness Recovery Action Planning (WRAP) (BEHAVIORAL).

Who is sponsoring clinical trial NCT01024569?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01024569's enrollment target sits among peer trials

555 184th of 2000 higher than 1,817 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06799000 · 555 participants · Phase 3

    A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

  • NCT06840392 · 555 participants · Phase 3

    A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

  • NCT06074588 · 556 participants · Phase 3

    Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

  • NCT06693622 · 556 participants

    Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01024569, the US trial registry maintained by the National Library of Medicine. NCT01024569 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.